38681-77-5 Usage
Uses
Used in Research and Pharmaceutical Industries:
4-AMINO-N-CYCLOPROPYLBENZAMIDE is utilized as an enzyme inhibitor in research and pharmaceutical applications, due to its potential to modulate the activity of specific enzymes. This property makes it a valuable tool in studying enzyme functions and developing new therapeutic agents.
Used in Medicinal Chemistry and Drug Development:
In the field of medicinal chemistry, 4-AMINO-N-CYCLOPROPYLBENZAMIDE serves as a building block for the synthesis of other organic molecules. Its unique structure allows for the creation of novel compounds with potential therapeutic applications, contributing to the advancement of drug development.
However, it is important to note that the specific uses and properties of 4-AMINO-N-CYCLOPROPYLBENZAMIDE have not been extensively studied and documented in the scientific literature. Further research is required to fully understand its potential applications and effects, ensuring its safe and effective use in various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 38681-77-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,8,6,8 and 1 respectively; the second part has 2 digits, 7 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 38681-77:
(7*3)+(6*8)+(5*6)+(4*8)+(3*1)+(2*7)+(1*7)=155
155 % 10 = 5
So 38681-77-5 is a valid CAS Registry Number.
InChI:InChI=1/C10H12N2O/c11-8-3-1-7(2-4-8)10(13)12-9-5-6-9/h1-4,9H,5-6,11H2,(H,12,13)
38681-77-5Relevant academic research and scientific papers
OXAZOLIDINONE DERIVATIVES AS PPAR LIGANDS
-
Paragraph 0150; 0175, (2016/06/28)
The present invention relates to a family of differently substituted oxazolidinones and to the pharmaceutically acceptable salts, esters, prodrugs, tautomers, solvates and hydrates thereof, which show affinity for the alpha and gamma subtypes of the perox
Novel Oxazolidinone-Based Peroxisome Proliferator Activated Receptor Agonists: Molecular Modeling, Synthesis, and Biological Evaluation
Fresno,Macías-González,Torres-Zaguirre,Romero-Cuevas,Sanz-Camacho,Elguero,Pavón,Rodríguez De Fonseca,Goya,Pérez-Fernández
, p. 6639 - 6652 (2015/09/07)
(Figure Presented). A series of new peroxisome proliferator activated receptors (PPARs) chiral ligands have been designed following the accepted three-module structure comprising a polar head, linker, and hydrophobic tail. The majority of the ligands inco
SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL AS KINASE INHIBITORS
-
Page/Page column 48, (2009/10/09)
The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I imidazopyridazines inhibit protein kinase activity thereby making them useful as anticancer agents.
